LB Pharmaceuticals
LBRX
LB Pharmaceuticals (LBRX) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $60.00 from $45.00 | Aug 24, 2026 |
| BMO Capital | Maintained | Outperform | $54.00 from $46.00 | Aug 12, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $45.00 | Aug 3, 2026 |
| BMO Capital | Initiated Coverage | Outperform | $46.00 | Jul 21, 2026 |
| Wolfe Research | Initiated Coverage | Outperform | $45.00 | Jul 7, 2026 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $45.00 | Apr 27, 2026 |
| Craig-Hallum | Initiated Coverage | Buy | $36.00 | Apr 10, 2026 |
| Stifel | Maintained | Buy | $40.00 from $35.00 | Mar 27, 2026 |
| Stifel | Maintained | Buy | $35.00 from $27.00 | Dec 11, 2025 |
| Piper Sandler | Initiated Coverage | Overweight | $78.00 | Oct 6, 2025 |
| Leerink Partners | Initiated Coverage | Outperform | $34.00 | Oct 6, 2025 |
| Stifel | Initiated Coverage | Buy | $27.00 | Oct 6, 2025 |
Frequently asked questions
What is the latest analyst rating on LBRX?
On Aug 24, 2026, HC Wainwright & Co. maintained LB Pharmaceuticals at Buy with a price target of $60.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.